NLRP3 modulators

US10556903B2 · kind B2 · utility

Assignee

• Innate Tumor Immunity, Inc. · US

Inventors

• Gary D. Glick · Ann Arbor, US
• Shomir Ghosh · Brookline, US
• William R. Roush · West Jupiter, US
• Edward J. Olhava · Newton, US

Key dates

• Filing date: Apr 19, 2017
• Grant date: Feb 11, 2020
• Expiry date: Apr 19, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure features compounds of Formula I, or a pharmaceutically acceptable salt thereof: in which R1, R2, R3, and R4 are as defined herein. These compounds are modulators of NLRP3, which are useful, e.g., for treating a condition, disease or disorder in which a decrease in NLRP3 activity (e.g., a condition, disease or disorder associated with repressed or impaired NLRP3 signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.